Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$272 Mln
P/E Ratio
--
P/B Ratio
4.74
Industry P/E
--
Debt to Equity
--
ROE
-0.51 %
ROCE
-56.63 %
Div. Yield
0 %
Book Value
13759.19
EPS
-3896.6
CFO
$-37.43 Mln
EBITDA
$-60.37 Mln
Net Profit
$-59.98 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
| 94.14 | 13.59 | 3.01 | 1,200.15 | 52.89 | 1.85 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Monopar Therapeutics (MNPR)
| 1,167.39 | -85.65 | -26.17 | -47.55 | -63.13 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator... receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Read more
Co-Founder, CEO, President & Director
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, CEO, President & Director
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Headquarters
Wilmette, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Monopar Therapeutics Inc (MNPR) stood at $ 60,291 Mln as on 31-Dec-24
The share price of Monopar Therapeutics Inc (MNPR) is $42.71 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Monopar Therapeutics Inc (MNPR) has given a return of 52.89% in the last 3 years.
Monopar Therapeutics Inc (MNPR) has a market capitalisation of $ 272 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Monopar Therapeutics Inc (MNPR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Monopar Therapeutics Inc (MNPR) and enter the required number of quantities and click on buy to purchase the shares of Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
The CEO & director of Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc. is Monopar Therapeutics Inc (MNPR), and CFO & Sr. VP is Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc.
There is no promoter pledging in Monopar Therapeutics Inc (MNPR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Monopar Therapeutics Inc. (MNPR) | Ratios |
|---|---|
|
Return on equity(%)
|
-56.63
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Monopar Therapeutics Inc (MNPR) was $0 Mln.
$-1.86
(
